TIGIT and leukemia: TIGIT blockade in M2 macrophages led to macrophage repolarization toward proinflammatory M1 phenotype, an increase in stimulatory receptor CD226 expression, and enhanced CD47-mediated phagocytosis, demonstrating that TIGIT on leukemia-associated macrophages can be targeted for therapeutic purposes144.